Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VICTORY: Tovorafenib + Vinblastine in Pediatric LGG
NCT06381570Phase 1Recruiting
- Start
- Mar 2024
- Primary completion
- Mar 2027
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tovorafenib in glioma. Primary endpoints: Maximum Tolerated Dose / Recommended Phase 2 Dose at 2 years, Safety and Tolerability at 2 years and 1 more. Started Mar 2024; status: recruiting.
02
Drugs
tovorafenib
03
Conditions
glioma
Beyond the preview
Go deeper on NCT06381570.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06381570.